23082-50-0

Basic information

• Product Name: 2-CHLORO-5-NITROACETOPHENONE
• Synonyms: 2'-CHLORO-5'-NITROACETOPHENONE;2-CHLORO-5-NITROACETOPHENONE;1-(2-CHLORO-5-NITRO-PHENYL)-ETHANONE;1-(2-chloro-5-nitrophenyl)ethan-1-one;Ethanone, 1-(2-chloro-5-nitrophenyl)-
• CAS NO: 23082-50-0
• Molecular Formula: C₈H₆ClNO₃
• Molecular Weight: 199.59
• EINECS: 245-421-2
• Product Categories: Carbonyl Compounds;Aromatic Acetophenones & Derivatives (substituted);pharmacetical
• Mol File: 23082-50-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 62 °C(Solv: ethanol (64-17-5))
• Boiling Point: 244.787 °C at 760 mmHg
• Flash Point: 101.844 °C
• Appearance: /
• Density: 1.379 g/cm³
• Vapor Pressure: 0.0298mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• CAS DataBase Reference: 2-CHLORO-5-NITROACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5-NITROACETOPHENONE(23082-50-0)
• EPA Substance Registry System: 2-CHLORO-5-NITROACETOPHENONE(23082-50-0)

Safety Data

• Hazardous Substances Data: 23082-50-0(Hazardous Substances Data)

Usage

General Description

2-CHLORO-5-NITROACETOPHENONE is a chemical compound with the molecular formula C8H6ClNO3. It is a yellow crystalline solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 2-CHLORO-5-NITROACETOPHENONE is known for its nitro group, which makes it reactive and useful in organic synthesis. 2-CHLORO-5-NITROACETOPHENONE is a versatile building block in the production of various organic compounds, and its structure makes it valuable in the creation of diverse chemical products.

InChI:InChI=1/C8H6ClNO3/c1-5(11)7-4-6(10(12)13)2-3-8(7)9/h2-4H,1H3

Upstream product

• 2142-68-9 1-(2-chlorophenyl)ethanone 
• 25784-91-2 2-chloro-5-nitrobenzoylchloride 
• 7697-37-2 nitric acid 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 35227-78-2 diethyl (ethoxymagnesio)malonate 
• 94088-68-3 2-(2-Chloro-5-nitro-benzoyl)-malonic acid diethyl ester 

Downstream Products

• 101513-55-7 4'-acetamino-2-methylcarbonyl-4-nitro-diphenylsulfone 
• 1026435-40-4 1-(2-azocan-1-yl-5-nitro-phenyl)-ethanone 
• 133659-66-2 1-(2-dimethylamino-5-nitro-phenyl)-ethanone 
• 79110-06-8 2-ethanoly-4-nitro-N-phenylaniline 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 363618-30-8 1-[2-(5-amino-6-methoxy-pyrimidin-4-ylsulfanyl)-5-nitro-phenyl]-ethanone 
• 363618-31-9 1-[2-(5-amino-6-dimethylamino-pyrimidin-4-ylsulfanyl)-5-nitro-phenyl]-ethanone 
• 917101-82-7 1-chloro-4-nitro-2-(prop-1-en-2-yl)benzene 
• 1056165-61-7 (2E)-3-(dimethylamino)-1-(2-chloro-5-nitrophenyl)prop-2-en-1-one 
• 1224978-35-1 N-cyclohexyl-5-nitrobenzo[b]thiophen-3-amine 
• 1224978-32-8 N-benzyl-5-nitrobenzo[b]thiophen-3-amine 
• 945454-01-3 ethyl 2-(1-(2-chloro-5-nitrophenyl)ethylidene)hydrazinecarboxylate 
• 879088-41-2 4-chloro-3-(pyridin-2-yl)benzeneamine 
• 879085-55-9 vismodegib 

Relevant articles and documents

Manufacturing Development and Genotoxic Impurity Control Strategy of the Hedgehog Pathway Inhibitor Vismodegib

The development work toward the robust and efficient manufacturing process to vismodegib, the active pharmaceutical ingredient (API) in Erivedge, is described. The optimization of the four-stage manufacturing process was designed to produce the API with the required critical quality attributes: (1) the selective catalytic hydrogenation reduction of the nitro compound 3 to the corresponding aniline 4 while minimizing the formation of potential genotoxic (mutagenic) impurities; (2) the control of the polymorphic phase and multipoint specification for particle size distribution.

Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof

Benzenesulphonamide compounds of general formula (I), wherein R1is a hydrogen or halogen atom such as chlorine or fluorine, or a straight or branched C1-4alkyl or C1-4alkoxy group, each of R2, R3and R4, which are the same or different, is a hydrogen atom or a straight, branched or cyclic C1-4alkyl group, and R1is a hydrogen atom or a C1-2alkyl, C1-2fluoroalkyl or C1-2perfluoroalkyl group, in the form of enantiomers, diastereoisomers or mixtures thereof, including racemic mixtures, as well as pharmaceutically acceptable acid addition salts thereof, are provided for therapeutical use.

Process for the production of nitro derivatives of aromatic compounds

Nitroderivates of aromatic compounds which are difficult to nitrate, can readily be obtained by nitration providing that the aromatic compound is treated with nitric acid or another nitrating agent in the presence of aliphatic or cycloaliphatic hydrocarbons monosubstituted or polysubstituted by halogen, the nitro group or an alkyl sulphonyl group, and the nitro derivative formed subsequently isolated.